Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Main finding · Incident dementiaResult — go to the resultAdjusted hazard ratio 0.80 95% CI 0.71–0.89Authors' conclusion
SGLT2 inhibitors showed an association with lower dementia risk in older people with T2D. Randomized controlled trials are warranted.
Study context
- Population
- Ontario residents aged ≥66 years with T2D, new users of an SGLT2i or DPP-4i, 1 July 2016 to 31 March 2021
- Participants
- 106,903 residents
- Exposure
- New use of SGLT2i vs DPP-4i
- Outcome
- Time to incident dementia (validated algorithm for Alzheimer's disease and related dementias)
- Follow-up
- Mean 2.80 years from cohort entry
Methodological detailspropensity score-weighted, 1-year lag time
- Propensity score-weighted
- 1-year lag time
Main finding
Incident dementia · mean follow-up 2.80 years
Adjusted hazard ratio
0.80
95% CI 0.71–0.89
SGLT2 inhibitorsvs DPP-4 inhibitors
aHR 0.80 (95% CI 0.71–0.89)
As reported in the abstract
- Incidence rate reported
- 14.2/1,000 person-years
Observational data: associations, not effects.
Further findings
Dementia, stratified by SGLT2i agent
- Dapagliflozin, lowest risk: aHR
- 0.67 (0.53-0.84) (95% CI)
- Empagliflozin: aHR
- 0.78 (0.69-0.89) (95% CI)
- Canagliflozin, no association: aHR
- 0.96 (0.80-1.16) (95% CI)
Dementia, as-treated analysis
- As-treated analysis: larger association than ITT analysis, aHR
- 0.66 (0.57-0.76) (95% CI)
Original publication
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Diabetes Care. Published 12 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →